DNTH Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.2M
+59.0%
761.0K
+64.4%
463.0K
+63.0%
284.0K
-28.3%
396.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
1.2M
+59.0%
761.0K
+64.4%
463.0K
+63.0%
284.0K
-28.3%
396.0K
Operating Expenses
59.7M
-4.1%
62.2M
+32.4%
47.0M
-32.7%
69.8M
+71.6%
40.7M
R&D
45.6M
-6.3%
48.7M
+41.0%
34.5M
-42.4%
59.9M
+84.4%
32.5M
SG&A
14.1M
+3.9%
13.6M
+8.7%
12.5M
+25.6%
9.9M
+21.2%
8.2M
Operating Income
-58472000
+4.9%
-61482000
-32.1%
-46533000
+33.1%
-69541000
-72.6%
-40288000
EBITDA
-58435000
+4.9%
-61445000
-32.1%
-46501000
+33.1%
-69514000
-72.7%
-40261000
Net Income
-46643000
+7.1%
-50215000
-23.0%
-40834000
+36.6%
-64432000
-75.3%
-36765000
EPS (Basic)
$-0.81
+10.0%
$-0.90
-5.9%
$-0.85
+40.6%
$-1.43
-47.4%
$-0.97
EPS (Diluted)
$-0.81
+10.0%
$-0.90
-5.9%
$-0.85
+40.6%
$-1.43
-47.4%
$-0.97
Shares (Diluted)
57.3M
+2.3%
56.0M
+16.6%
48.0M
+6.6%
45.1M
+19.2%
37.8M
Dianthus Therapeutics (DNTH) — Financials